The US Food and Drug Administration has given de novo authorization to Medtronic plc and Cosmo Pharmaceuticals N.V.’s GI Genius endoscopy module. The device is the first of its kind to use artificial intelligence to help detect lesions during a colonoscopy, which could have major implications for fighting colon cancer.
The agency announced on 12 April that it had granted marketing authorization to the product, which has been trained to spot polyps and potential tumors using machine learning. The GI...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?